UY30723A1 - Compuestos de biciclocarboxiamida sustituidos - Google Patents

Compuestos de biciclocarboxiamida sustituidos

Info

Publication number
UY30723A1
UY30723A1 UY30723A UY30723A UY30723A1 UY 30723 A1 UY30723 A1 UY 30723A1 UY 30723 A UY30723 A UY 30723A UY 30723 A UY30723 A UY 30723A UY 30723 A1 UY30723 A1 UY 30723A1
Authority
UY
Uruguay
Prior art keywords
compounds
biciclocarboxyamide
substituted
provides
compound
Prior art date
Application number
UY30723A
Other languages
English (en)
Spanish (es)
Inventor
Koji Ando
Andrew Antony Calabrese
Satoshi Nagayama
Misato Hirano
Mattew Alexander James Duncton
Kentaro Futatsugi
Original Assignee
Pfizer
Renovis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Renovis Inc filed Critical Pfizer
Publication of UY30723A1 publication Critical patent/UY30723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY30723A 2006-11-17 2007-11-16 Compuestos de biciclocarboxiamida sustituidos UY30723A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86628506P 2006-11-17 2006-11-17
US94393307P 2007-06-14 2007-06-14
US98334307P 2007-10-29 2007-10-29

Publications (1)

Publication Number Publication Date
UY30723A1 true UY30723A1 (es) 2008-07-03

Family

ID=39311049

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30723A UY30723A1 (es) 2006-11-17 2007-11-16 Compuestos de biciclocarboxiamida sustituidos

Country Status (12)

Country Link
US (1) US7964732B2 (enExample)
EP (1) EP2091944B1 (enExample)
JP (1) JP2010510202A (enExample)
AR (1) AR064253A1 (enExample)
AT (1) ATE509925T1 (enExample)
CA (1) CA2669915C (enExample)
CL (1) CL2007003289A1 (enExample)
GT (1) GT200700103A (enExample)
PE (1) PE20081504A1 (enExample)
TW (1) TW200831089A (enExample)
UY (1) UY30723A1 (enExample)
WO (1) WO2008059370A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL2427436T3 (pl) * 2009-05-07 2013-06-28 Gruenenthal Gmbh Podstawione aromatyczne pochodne karboksamidu i mocznika jako ligandy receptora waniloidowego
RU2553392C2 (ru) 2009-05-07 2015-06-10 Грюненталь Гмбх Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
WO2012025469A1 (en) * 2010-08-24 2012-03-01 Solvay Sa Improved process for the preparation of esters of 1-h-pyrazole-4-carboxylic acids
EP2638015A1 (en) * 2010-11-10 2013-09-18 Grünenthal GmbH Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands
JP5140776B1 (ja) * 2012-09-05 2013-02-13 タマ化学工業株式会社 １−置換−３−フルオロアルキルピラゾール−４−カルボン酸エステルの製造方法
BR122020001830B1 (pt) 2015-05-18 2023-02-28 Shenyang Sinochem Agrochemicals R&D Co., LTD Compostos pirazol substituídos contendo pirimidinila, preparação e aplicação dos mesmos
AR112673A1 (es) 2017-08-11 2019-11-27 Syngenta Participations Ag Derivados de pirazol activos como plaguicidas
WO2020164994A1 (en) 2019-02-13 2020-08-20 Syngenta Crop Protection Ag Pesticidally active pyrazole derivatives
WO2020164993A1 (en) 2019-02-13 2020-08-20 Syngenta Crop Protection Ag Pesticidally active pyrazole derivatives
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
CN110734401A (zh) * 2019-10-10 2020-01-31 长沙麓兴生物科技有限公司 一种氮未取代-4-甲酰基吡唑的制备方法
CN114989546B (zh) * 2022-07-05 2023-07-28 上海乐纯生物技术有限公司 一种用于细胞治疗储液袋生产的fep膜
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2671059B2 (ja) 1990-11-30 1997-10-29 富士レビオ株式会社 ナフトエ酸誘導体
AU5006693A (en) 1992-08-07 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Polyhydroxylated naphthyl 2-carboxylate, and quinolyl and isoquinolyl 3-carboxylate derivatives as protein tyrosine kinase inhibitors
AU674613B2 (en) 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
DE4423353A1 (de) 1994-07-04 1996-01-11 Bayer Ag Verfahren zur Herstellung N-acylierter 2-Chlor-5-aminomethylpyridine
US5753700A (en) 1994-12-28 1998-05-19 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
AU1457299A (en) 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
AU771358B2 (en) 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP1147214B1 (en) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
AU5158100A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
CH1196397H1 (de) 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
DE50006615D1 (de) 1999-08-07 2004-07-01 Boehringer Ingelheim Pharma Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE19963179B4 (de) 1999-12-27 2009-02-05 Grünenthal GmbH Substituierte 1- und 2-Naphthol-Mannichbasen
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
NZ523882A (en) 2000-08-21 2004-11-26 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
JP2005501873A (ja) 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
CA2462289C (en) 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003030937A1 (en) 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
ATE416168T1 (de) 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
TW200306159A (en) 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
GB2403474B (en) 2002-04-18 2006-10-11 Inst Med Molecular Design Inc Amide derivatives
WO2003104178A1 (en) 2002-06-07 2003-12-18 Cortical Pty Ltd Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
GB2389580A (en) 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
US20040176366A1 (en) 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
EP1581498A2 (en) 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7179427B2 (en) * 2002-11-25 2007-02-20 Abb Lummus Global Inc. Apparatus for countercurrent contacting of gas and solids
AU2003287880A1 (en) 2002-12-11 2004-06-30 7Tm Pharma A/S Cyclic quinoline compounds for use in mch receptor related disorders
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
JP2006519258A (ja) 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
MXPA05012278A (es) 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
CA2529154C (en) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
KR100707123B1 (ko) 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
SE0302323D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
EP1660503A1 (en) 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
US20050232818A1 (en) * 2003-09-19 2005-10-20 Donald Sandell Single sheet seal applicator and cartridge
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
US7553848B2 (en) 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MXPA06012333A (es) 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤

Also Published As

Publication number Publication date
TW200831089A (en) 2008-08-01
AR064253A1 (es) 2009-03-25
CA2669915A1 (en) 2008-05-22
CA2669915C (en) 2012-02-07
WO2008059370A8 (en) 2009-06-04
WO2008059370A2 (en) 2008-05-22
WO2008059370A3 (en) 2008-07-24
ATE509925T1 (de) 2011-06-15
US20100267769A1 (en) 2010-10-21
GT200700103A (es) 2008-11-04
EP2091944B1 (en) 2011-05-18
EP2091944A2 (en) 2009-08-26
CL2007003289A1 (es) 2008-06-20
JP2010510202A (ja) 2010-04-02
PE20081504A1 (es) 2008-10-30
US7964732B2 (en) 2011-06-21

Similar Documents

Publication Publication Date Title
GT200600114A (es) Derivados de ciclopropanocarboxamida
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
PA8740901A1 (es) Compuestos organicos
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
CR8919A (es) Analogos de tetrapeptidos
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
SV2006002187A (es) Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
ECSP11011151A (es) Compuestos purina
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CO6341625A2 (es) Derivados de indol como agentes anticáncer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170731